Li Xiaoxuan, Zhang Shuo, Li Shanshan, Yu Mengxia, Yao Tianying, Shen Yuxin, Li Jiang, Chen Mingxia
{"title":"胰腺癌患者财务毒性轨迹的预测因素:潜在类别增长分析","authors":"Li Xiaoxuan, Zhang Shuo, Li Shanshan, Yu Mengxia, Yao Tianying, Shen Yuxin, Li Jiang, Chen Mingxia","doi":"10.1002/cam4.70875","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Importance</h3>\n \n <p>Pancreatic cancer patients face varying medical expenses at different stages of treatment, resulting in dynamic changes in their financial toxicity. Longitudinal data collection is necessary to characterize the trajectory of these financial toxicity changes.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To Explore Potential Trajectories and Influencing Factors of Financial Toxicity among Pancreatic Cancer Patients.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>This was a prospective observational research study performed according to STROBE Checklist.</p>\n </section>\n \n <section>\n \n <h3> Setting and Participants</h3>\n \n <p>From August 2022 to August 2023, we conducted inpatient data collection from pancreatic cancer patients in three hospitals in Jiangsu Province.</p>\n \n <p>Main Outcomes and Measures.</p>\n \n <p>The COST scale was employed to investigate financial toxicity at four time points: upon admission (T0), at discharge (T1), 3 months post-discharge (T2), and 6 months post-discharge (T3). A latent growth model was utilized to classify the trajectories of financial toxicity and explore its influencing factors.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The identification of financial toxicity trajectories among pancreatic cancer patients revealed three potential categories: a high-risk-financial toxicity stable group (19.69%), a moderate-risk-financial toxicity stable group (56.37%), and a low-risk-financial toxicity stable group (23.94%). Logistic regression analysis showed that, compared to the low-risk-financial toxicity stable group, the primary influencing factors for the high-risk-financial toxicity stable group were self-efficacy and total out-of-pocket medical expenses. In contrast to the low-risk-financial toxicity stable group, the moderate-risk-financial toxicity stable group was influenced by self-efficacy and total monthly household income. When comparing the moderate-risk-financial toxicity stable group to the high-risk-financial toxicity stable group, factors such as ACCI, employment status, total out-of-pocket medical expenses, and distance to healthcare facilities emerged as significant.</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Relevance</h3>\n \n <p>The financial toxicity among pancreatic cancer patients has been categorized into three distinct trajectory patterns, each exhibiting significant population heterogeneity. It is imperative that we acknowledge the profound impact of financial toxicity on pancreatic cancer patients and strengthen relevant preventive and control measures to enhance their quality of life and therapeutic outcomes.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 9","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70875","citationCount":"0","resultStr":"{\"title\":\"Predictors of Financial Toxicity Trajectories in Patients With Pancreatic Cancer: A Latent Class Growth Analysis\",\"authors\":\"Li Xiaoxuan, Zhang Shuo, Li Shanshan, Yu Mengxia, Yao Tianying, Shen Yuxin, Li Jiang, Chen Mingxia\",\"doi\":\"10.1002/cam4.70875\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Importance</h3>\\n \\n <p>Pancreatic cancer patients face varying medical expenses at different stages of treatment, resulting in dynamic changes in their financial toxicity. Longitudinal data collection is necessary to characterize the trajectory of these financial toxicity changes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To Explore Potential Trajectories and Influencing Factors of Financial Toxicity among Pancreatic Cancer Patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>This was a prospective observational research study performed according to STROBE Checklist.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Setting and Participants</h3>\\n \\n <p>From August 2022 to August 2023, we conducted inpatient data collection from pancreatic cancer patients in three hospitals in Jiangsu Province.</p>\\n \\n <p>Main Outcomes and Measures.</p>\\n \\n <p>The COST scale was employed to investigate financial toxicity at four time points: upon admission (T0), at discharge (T1), 3 months post-discharge (T2), and 6 months post-discharge (T3). A latent growth model was utilized to classify the trajectories of financial toxicity and explore its influencing factors.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The identification of financial toxicity trajectories among pancreatic cancer patients revealed three potential categories: a high-risk-financial toxicity stable group (19.69%), a moderate-risk-financial toxicity stable group (56.37%), and a low-risk-financial toxicity stable group (23.94%). Logistic regression analysis showed that, compared to the low-risk-financial toxicity stable group, the primary influencing factors for the high-risk-financial toxicity stable group were self-efficacy and total out-of-pocket medical expenses. In contrast to the low-risk-financial toxicity stable group, the moderate-risk-financial toxicity stable group was influenced by self-efficacy and total monthly household income. When comparing the moderate-risk-financial toxicity stable group to the high-risk-financial toxicity stable group, factors such as ACCI, employment status, total out-of-pocket medical expenses, and distance to healthcare facilities emerged as significant.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions and Relevance</h3>\\n \\n <p>The financial toxicity among pancreatic cancer patients has been categorized into three distinct trajectory patterns, each exhibiting significant population heterogeneity. It is imperative that we acknowledge the profound impact of financial toxicity on pancreatic cancer patients and strengthen relevant preventive and control measures to enhance their quality of life and therapeutic outcomes.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 9\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70875\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70875\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70875","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Predictors of Financial Toxicity Trajectories in Patients With Pancreatic Cancer: A Latent Class Growth Analysis
Importance
Pancreatic cancer patients face varying medical expenses at different stages of treatment, resulting in dynamic changes in their financial toxicity. Longitudinal data collection is necessary to characterize the trajectory of these financial toxicity changes.
Objective
To Explore Potential Trajectories and Influencing Factors of Financial Toxicity among Pancreatic Cancer Patients.
Design
This was a prospective observational research study performed according to STROBE Checklist.
Setting and Participants
From August 2022 to August 2023, we conducted inpatient data collection from pancreatic cancer patients in three hospitals in Jiangsu Province.
Main Outcomes and Measures.
The COST scale was employed to investigate financial toxicity at four time points: upon admission (T0), at discharge (T1), 3 months post-discharge (T2), and 6 months post-discharge (T3). A latent growth model was utilized to classify the trajectories of financial toxicity and explore its influencing factors.
Results
The identification of financial toxicity trajectories among pancreatic cancer patients revealed three potential categories: a high-risk-financial toxicity stable group (19.69%), a moderate-risk-financial toxicity stable group (56.37%), and a low-risk-financial toxicity stable group (23.94%). Logistic regression analysis showed that, compared to the low-risk-financial toxicity stable group, the primary influencing factors for the high-risk-financial toxicity stable group were self-efficacy and total out-of-pocket medical expenses. In contrast to the low-risk-financial toxicity stable group, the moderate-risk-financial toxicity stable group was influenced by self-efficacy and total monthly household income. When comparing the moderate-risk-financial toxicity stable group to the high-risk-financial toxicity stable group, factors such as ACCI, employment status, total out-of-pocket medical expenses, and distance to healthcare facilities emerged as significant.
Conclusions and Relevance
The financial toxicity among pancreatic cancer patients has been categorized into three distinct trajectory patterns, each exhibiting significant population heterogeneity. It is imperative that we acknowledge the profound impact of financial toxicity on pancreatic cancer patients and strengthen relevant preventive and control measures to enhance their quality of life and therapeutic outcomes.
期刊介绍:
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.